The motion capture technology used in the film Avatar has inspired researchers to use AI to track rare diseases for early diagnosis. The technology, which was prominently used in the first Avatar film, allows artists to bring characters to life by analyzing data gathered by motion capture suits.
According to a recent report, Avatar’s AI tech has gained attention for its potential to monitor rare diseases. Researchers are now using motion technologies for tracking rare diseases through AI, which gives efficient support in finding the illness at an early stage.
Researchers have developed a new method of tracking the evolution of rare diseases using AI technology by utilising the motion-capture technology from the film Avatar.In a study that was published in the academic journal Medicines, researchers speculated that this AI-powered method would reduce the time and expense needed to develop new medications and conduct extensive clinical trials.
In two separate investigations, the technique has so far been tested on people with Duchenne muscular dystrophy and Friedreich’s ataxia (FA) / (DMD). They discovered that AI could predict how the illness would progress over the course of a year in less time than an expert could.
Researchers believe on same method is useful for monitoring the development of patients with movement impairing diseases, such as those that affect the heart, nervous system, brain, lungs, joints, and other mental problems.
The system is capable of carrying out in-depth assessments due to these predictive abilities. Scientists at Imperial College evaluated it on patients and discovered that it could anticipate the progression of the illness over a 12-month period.
The potential applications of motion capture technology in the healthcare industry are vast, and research continues to explore how it can be used to improve diagnosis and treatment for various diseases. By using AI to track rare diseases, researchers hope to improve the speed and accuracy of diagnosis, ultimately leading to better patient outcomes.